Analysts expect Caris Life Sciences to report Q3 2026 revenue of approximately $255.34 million and earnings per share of $0.03, with the stock currently trading at $34.23 against an average analyst price target of $33.67.
Investors are primarily focused on clinical case volume, with expectations for the company to achieve between 61,000 and 62,000 cases for the quarter, representing roughly 20% year-over-year growth.
The market is also evaluating the commercial adoption of the Caris Detect multi-cancer early detection test, which launched earlier this year and is critical to reaching management's tripling of annual revenue capacity.
Following a record second quarter, investors will look for updates to the full-year 2026 revenue guidance, which was recently raised to a range of $1.03 billion to $1.04 billion.